ArticleMolecular pharmaceutics2025
Machine Learning Prediction and Validation of Plasma Concentration-Time Profiles.
Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Machine Learning-Driven Prediction of Dose-Linear Pharmacokinetics: Utilizing Molecular Descriptors to Guide Formulation Strategy.ACS omega · 2026Article
- Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology.NPJ precision oncology · 2025Review
- Methodological Techniques Used in Machine Learning to Support Individualized Drug Dosing Regimens Based on Pharmacokinetic Data: A Scoping Review.Clinical pharmacokinetics · 2025Article
- Machine learning-based prediction model for teicoplanin plasma concentrations in adults with liver disease using real-world data.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent research has increasingly focused on using machine learning for covariate selection in population pharmacokinetics (PPK) analysis. However, few studies have explored the prediction of plasma concentration profiles of drugs using nonlinear mixed-effect models combined with machine learning. This gap includes limited validation of prediction accuracy and applicability to diverse patient populations and dosing conditions. This study addresses these gaps by using remifentanil as a model drug and applying machine learning models to predict plasma concentration profiles based on virtual and real-world data. We created various training data sets for the virtual data by clustering based on the size and diversity of the test data set. Our results demonstrated high prediction accuracy for virtual and real-world data sets using Random Forest models. These results suggest that machine learning models are effective for large-scale data sets and real-world data with variable dosing times and amounts per patient. Considering the efficiency of machine learning, it offers a fit-for-purpose approach alongside traditional PPK methods, potentially enhancing future pharmacokinetic and pharmacodynamic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.